奎斯特诊疗 2026年季度报告

FORM 10-Q (Mark One) For the quarterly period ended March 31, 2026 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated 16-1387862(I.R.S. Employer Identification Number) (State of Incorporation)500 Plaza DriveSecaucus,NJ 07094(973) 520-2700 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. ☒Accelerated filer☐Smaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of April15, 2026, there were outstanding 110,696,429 shares of the registrant’s common stock, $.01 par value. PART I - FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) Index to unaudited consolidated financial statements filed as part of this report:Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20252Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2026 and 20253Consolidated Balance Sheets as of March 31, 2026 and December 31, 20254Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20255Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026 and 20256Notes to Consolidated Financial Statements(unaudited)7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsManagement’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3. Quantitative and Qualitative Disclosures About Market RiskSee Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”33Item 4. Controls and ProceduresControls and Procedures33 QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED MARCH31, 2026 AND 2025(unaudited)(in millions, except per share data) Net revenues Operating costs and expenses and other operating income: Cost of servicesSelling, general and administrativeAmortization of intangible assetsOther operating expense, netTotal operating costs and expenses, net Operating income Other income (expense):Interest expense, netOther expense, netTotal non-operating expense, net Income before income taxes and equity in earnings of equity method investeesIncome tax expenseEquity in earnings of equity method investees, net of taxesNet incomeLess: Net income attributable to noncontrolling interestsNet income attributable to Quest Diagnostics Earnings per share attributable to Quest Diagnostics’ common stockholders:BasicDiluted Weighted average common shares outstanding:BasicDiluted QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEFOR THE THREE MONTHS ENDED MARCH31, 2026 AND 2025(unaudited)(in millions) Three Months EndedMarch 31, Net income Other comprehensive income (loss):Foreign currency translation adjustmentOther comprehensive (loss) income Comprehensive incomeLess: Comprehensive income attributable to noncontrolling interestsComprehensive income attributable to Quest Diagnostics QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSMARCH31, 2026 AND DECEMBER31, 2025(unaudited)(in millions, except per share data) QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH31, 2026 AND 2025(unaudited)(in millions) Cash flows from operating activities: Cash flows from investing activities:Business acquisitions, net of cash acquiredCapital expendituresOther investing act